Current Releases
Archived Releases
Media Coverage

Return to Press Releases View Archived

February 14, 2007

For immediate release

NUCRYST Pharmaceuticals announces year-end results
Company to pursue 510(k) approval for anti-microbial barrier cream

Wakefield, Massachusetts – February 14, 2007 –  NUCRYST Pharmaceuticals Corp. today announced that for the year ended December 31, 2006, it recorded a net loss of $10.5 million, or 58 cents per share on revenues of $24.4 million, compared to a net loss of $2.6 million, or 27 cents per share on revenues of $23.6 million in the previous year. The 2005 results were aided by a $5-million milestone payment whereas no milestone was earned in 2006.

The higher net loss for the year is attributable to higher general and administrative costs as a result of becoming a public company in December 2005 and higher research and development costs relating to the continuation into the third quarter of 2006 of the second Phase 2 dermatological clinical study that commenced in the third quarter of 2005.

For the three months ended December 31, 2006, the company posted a net loss of $1.6 million, or 9 cents per share, on revenues of $4.5 million compared to a net loss of $2.8 million, or 29 cents per share, on revenues of $4.8 million in the fourth quarter of 2005.

At December 31, 2006, NUCRYST had $19 million in cash and cash equivalents.

“2006 represented our first year as a publicly traded company,” said Scott H. Gillis, President & CEO of NUCRYST. “Our wound care manufacturing business continued to grow through our relationship with Smith & Nephew plc. In 2007, we will continue with our pharmaceutical gastrointestinal program and plan to pursue short and medium term product opportunities for our unique, patent-protected nanocrystalline silver.”

In the fourth quarter of 2006, NUCRYST reported cancellation of the clinical program for topical formulation of NPI 32101 as a pharmaceutical candidate for the treatment of atopic dermatitis. In response to this outcome, NUCRYST intends to implement a limited restructuring of the company’s operations in the first quarter of 2007 to preserve its cash position. This will include shifting the focus of research and development efforts from clinical work towards preclinical work for NUCRYST’s nanocrystalline technology and exploring near term revenue opportunities.

As the first near term opportunity, NUCRYST is pursuing a 510(k) clearance to market a moisturizing cream containing NPI 32101, NUCRYST’s patent-protected nanocrystalline silver, as a barrier to infection. The company filed a 510(k) application with the US Food & Drug Administration in December 2006. The NPI 32101 cream has a good safety profile, a stable formulation and is cosmetically-acceptable. If FDA clearance is received, NUCRYST intends to seek a partner with a specialized dermatology sales force to bring the product to market.

NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products under their Acticoat™ trade mark. Acticoat™ products incorporate NUCRYST’s SILCRYST™ coatings and are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The Company has developed its proprietary nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, referred to as NPI 32101.

A more detailed discussion of NUCRYST’s 2006 year end results can be found in the 2006 Consolidated Financial Statements and Management’s Discussion and Analysis, which will be available at and NUCRYST filings are also available at


For more information contact:
David Wills
Investor Relations
NUCRYST Pharmaceuticals Corp.
(416) 504-8464

All amounts in US dollars
SILCRYST™ is a trademark of NUCRYST Pharmaceuticals Corp.
Acticoat™ is a trademark of Smith & Nephew plc

The financial results in this news release are unaudited, and are not a complete disclosure of our quarterly or annual financial results.

Some of the statements above may constitute forward-looking statements within the meaning of securities legislation in the United States and Canada (collectively “forward looking statements”).  The words “intends”, “will”, and “plan” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this news release include, but are not limited to, statements about: prospects and plans for the development of future products containing our nanocrystalline silver, plans for our gastrointestinal program, plans for restructuring our operations, regulatory approval of our barrier cream, and plans and prospects for our barrier cream. With respect to the forward-looking statements contained in this news release, readers are cautioned that numerous risks, uncertainties and other factors could cause our actual results to differ materially from those indicated in these statements including, but not limited to: difficulties or delays in the initiation, timing, progress and results of our preclinical trials and research and development programs; we may not be able to obtain and retain regulatory approval for our barrier cream and any future products; our ability to maintain our collaboration with Smith & Nephew; our reliance on sales of Acticoat™ products with our SILCRYST™ coatings by Smith & Nephew; we may not be able to establish or maintain sales and marketing collaborations for our barrier cream; we may not be able to attract and retain collaborations relating to the development and commercialization of future products; our restructuring plans may not be sufficient to conserve cash and control expenses; competition from other silver-based pharmaceutical or medical device companies; our ability to raise additional financing required to fund further research and development, clinical studies and obtain regulatory approvals, on commercially acceptable terms or at all; our ability to protect our intellectual property rights and to not infringe on the intellectual property rights of others; our ability to comply with governmental regulations and standards; changes in general economic conditions; other risks and uncertainties unidentified at this time; management’s response to these factors; and other factors described under “Risk Factors” in our Quarterly Report on 10-Q for the quarter ended September 30, 2006, filed with the U.S. Securities and Exchange Commission at and with securities authorities in Canada at  All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.

View Financial Statements Q4 2006

Return to Press Releases View Archived

  • Stock Quote
  • Leadership
  • Join Email Club